Cargando…
The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes
BACKGROUND: To determine whether 12 months of intensive medical therapy (IMT) improves HDL functionality parameters in subjects with type II diabetes (T2D). METHODS: Retrospective, randomized, and controlled 12-month IMT intervention trial that enrolled 13-subjects with T2D (age 51- years, fasting g...
Autores principales: | , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2016
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002094/ https://www.ncbi.nlm.nih.gov/pubmed/27567897 http://dx.doi.org/10.1186/s12944-016-0314-4 |
_version_ | 1782450512374792192 |
---|---|
author | Kashyap, Sangeeta Kheniser, Karim Li, Ling Bena, James Kasumov, Takhar |
author_facet | Kashyap, Sangeeta Kheniser, Karim Li, Ling Bena, James Kasumov, Takhar |
author_sort | Kashyap, Sangeeta |
collection | PubMed |
description | BACKGROUND: To determine whether 12 months of intensive medical therapy (IMT) improves HDL functionality parameters in subjects with type II diabetes (T2D). METHODS: Retrospective, randomized, and controlled 12-month IMT intervention trial that enrolled 13-subjects with T2D (age 51- years, fasting glucose 147 mg/dL, body mass index [BMI] 36.5 kg/m(2)) and nine healthy control (46-years, fasting glucose 90 mg/dL, BMI 26.5 kg/m2). Subjects with T2D underwent IMT and HDL functionality measures (pro-inflammatory index of high-density lipoprotein (pHDL)), paraoxonase one (PON1), ceruloplasmin (Cp), and myeloperoxidase (MPO) activity were performed on samples at baseline and at 12-months following IMT. RESULTS: At baseline, pHDL index was significantly higher in subjects with T2D (p < 0.001) and apolipoprotein A-1 levels were significantly lower (p = 0.013) vs. controls. After 12-months, there was a trend for improved pHDL activity (p = 0.083), as indicated by intent-to-treat analysis, but when the non-adherent subject was omitted (per-protocol), significant attenuations in pHDL activity (p = 0.040) were noted; Δ pHDL activity at 12-months was associated with Δ weight (r = 0.62, p = 0.032) and Δ fasting glucose (r = 0.65, p = 0.022). Moreover, PON1 activity significantly improved (p < 0.001). The aforementioned occurred in association with improvements in inflammatory markers (i.e., C-reactive protein & tumor necrosis factor), hemoglobin A1C, fasting glucose, triglycerides, high-density lipoprotein levels and adipokines. CONCLUSION: IMT ameliorates pHDL index and significantly improves anti-oxidative function, as measured by PON1. Improvements in weight and fasting glucose mediated the decrease in pHDL index. Pharmacological aids and lifestyle modification are required to improve cardiovascular risk factors, subsequent mortality risk, and promote T2D remission. Application of either form of therapy alone may only have relatively miniscule effects on the aforementioned factors, in relation to the aggregate. |
format | Online Article Text |
id | pubmed-5002094 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2016 |
publisher | BioMed Central |
record_format | MEDLINE/PubMed |
spelling | pubmed-50020942016-08-28 The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes Kashyap, Sangeeta Kheniser, Karim Li, Ling Bena, James Kasumov, Takhar Lipids Health Dis Research BACKGROUND: To determine whether 12 months of intensive medical therapy (IMT) improves HDL functionality parameters in subjects with type II diabetes (T2D). METHODS: Retrospective, randomized, and controlled 12-month IMT intervention trial that enrolled 13-subjects with T2D (age 51- years, fasting glucose 147 mg/dL, body mass index [BMI] 36.5 kg/m(2)) and nine healthy control (46-years, fasting glucose 90 mg/dL, BMI 26.5 kg/m2). Subjects with T2D underwent IMT and HDL functionality measures (pro-inflammatory index of high-density lipoprotein (pHDL)), paraoxonase one (PON1), ceruloplasmin (Cp), and myeloperoxidase (MPO) activity were performed on samples at baseline and at 12-months following IMT. RESULTS: At baseline, pHDL index was significantly higher in subjects with T2D (p < 0.001) and apolipoprotein A-1 levels were significantly lower (p = 0.013) vs. controls. After 12-months, there was a trend for improved pHDL activity (p = 0.083), as indicated by intent-to-treat analysis, but when the non-adherent subject was omitted (per-protocol), significant attenuations in pHDL activity (p = 0.040) were noted; Δ pHDL activity at 12-months was associated with Δ weight (r = 0.62, p = 0.032) and Δ fasting glucose (r = 0.65, p = 0.022). Moreover, PON1 activity significantly improved (p < 0.001). The aforementioned occurred in association with improvements in inflammatory markers (i.e., C-reactive protein & tumor necrosis factor), hemoglobin A1C, fasting glucose, triglycerides, high-density lipoprotein levels and adipokines. CONCLUSION: IMT ameliorates pHDL index and significantly improves anti-oxidative function, as measured by PON1. Improvements in weight and fasting glucose mediated the decrease in pHDL index. Pharmacological aids and lifestyle modification are required to improve cardiovascular risk factors, subsequent mortality risk, and promote T2D remission. Application of either form of therapy alone may only have relatively miniscule effects on the aforementioned factors, in relation to the aggregate. BioMed Central 2016-08-27 /pmc/articles/PMC5002094/ /pubmed/27567897 http://dx.doi.org/10.1186/s12944-016-0314-4 Text en © The Author(s). 2016 Open AccessThis article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made. The Creative Commons Public Domain Dedication waiver (http://creativecommons.org/publicdomain/zero/1.0/) applies to the data made available in this article, unless otherwise stated. |
spellingShingle | Research Kashyap, Sangeeta Kheniser, Karim Li, Ling Bena, James Kasumov, Takhar The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes |
title | The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes |
title_full | The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes |
title_fullStr | The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes |
title_full_unstemmed | The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes |
title_short | The therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes |
title_sort | therapeutic efficacy of intensive medical therapy in ameliorating high-density lipoprotein dysfunction in subjects with type two diabetes |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5002094/ https://www.ncbi.nlm.nih.gov/pubmed/27567897 http://dx.doi.org/10.1186/s12944-016-0314-4 |
work_keys_str_mv | AT kashyapsangeeta thetherapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes AT kheniserkarim thetherapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes AT liling thetherapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes AT benajames thetherapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes AT kasumovtakhar thetherapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes AT kashyapsangeeta therapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes AT kheniserkarim therapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes AT liling therapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes AT benajames therapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes AT kasumovtakhar therapeuticefficacyofintensivemedicaltherapyinamelioratinghighdensitylipoproteindysfunctioninsubjectswithtypetwodiabetes |